Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients
High mobility group B1 (HMGB1) is a protein that is released from dying cancer cells in the context of immunogenic cell death (ICD). A recent study performed on patients with head and neck squamous cell carcinomas (HNSCC) reports that a chemoradiotherapy-induced increase in circulating HMGB1 levels...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Taylor & Francis Group
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/d1c3818d0e244f189784f14b906aeefd |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|